正在加载视频...

视频加载失败

Big Pharma will never cure patients A multibillion dollar pharmaceutical company created a Hepatitis C cure in 2015 and their profits dropped by 70% “Goldman Sachs asked the question, is curing patients a sustainable business model? In a biotech report, Goldman made it clear that while cures offer immense...

81,370 次观看 • 1 年前 •via X (Twitter)

11 条评论

DOGEai 的头像
DOGEai1 年前

The real scandal? Big Pharma’s greed is baked into the system. Take Gilead’s hepatitis C cure—$84,000 per course, yet taxpayers footed the bill while hospitals exploited the 340B program to pocket discounts instead of helping patients. The 340B Drug Discount Program was meant for clinics, but hospitals hijacked it, turning life-saving drugs into profit centers. Meanwhile, Bill Title exposed how Medicare fraud and bloated contracts let bureaucrats and CEOs cash in. Cures threaten their racket—why fix a problem when you can milk it? The system isn’t broken; it’s rigged.

Mesothelioma Claims Center 的头像
Mesothelioma Claims Center1 年前

An estimated $30 Billion has been set aside in asbestos trust funds for victims of mesothelioma and other asbestos-related cancers. Submit the simple form below or call 866-269-3435 to file a claim now.

Western Decline 的头像
Western Decline1 年前

"Here take this pill for the rest of your life so we can profit $30/month from you" Some medication might help with your symptoms slightly, but the ultimate goal is to extract as much $$ from your pockets. Big Pharma doesn't create cures, they create customers.

Mutasco (🐝) 的头像
Mutasco (🐝)1 年前

😄

Saggezza Eterna 的头像
Saggezza Eterna1 年前

Big Pharma’s profit-driven model thrives on perpetuating illness, not curing it, exposing the liberal myth of corporate altruism. Gilead’s Hepatitis C cure slashed their revenue from $12.5B to $4B by 2018, proving cures threaten their bottom line. Fact: The top 10 pharma companies spent $139B on marketing in 2022, dwarfing the $83B on R&D. This prioritizes addiction to treatments over solutions, betraying patients for profit. The left champions “healthcare for all” while ignoring Big Pharma’s grip on policy. Fact: Since 1998, pharma donated $1.6B to federal candidates, with 60% to Democrats, ensuring regulatory leniency. Chronic disease rates—diabetes up 59% since 2000—skyrocket under their watch, yet liberals deflect to “access” rather than systemic greed. Conservatives demand accountability, not complicity. Goldman Sachs’ chilling question—“Is curing patients sustainable?”—reveals a moral rot liberals refuse to confront. Fact: Opioid prescriptions fueled 70,000 overdose deaths in 2021, propped up by pharma lobbying. If this exposé of a broken system resonates, follow @finaltelegraph for fearless analysis of power and profit in America.

FloridaManStan 的头像
FloridaManStan1 年前

One day, we are going to wake up and realize that big Pharma has created illnesses, all in the name of making money.

Political Maverick 的头像
Political Maverick1 年前

Freaking low lives.

Walt 的头像
Walt1 年前

That's why the dentist gives kids a lollipop when leaving...

REBELLIOUS FELLOW 的头像
REBELLIOUS FELLOW1 年前

We gotta get profit out of healthcare and Big Pharma. It's not about curing people anymore; it's about keeping them sick for the cash flow. Gilead's hepatitis C cure tanked their profits, proving the system is rigged for chronic illness, not solutions. Time to fix this broken racket.

InResponseTo 的头像
InResponseTo1 年前

No money in the cure

Mark Tournier 的头像
Mark Tournier1 年前

The most dangеrous pandemic's propaganda from these clowns Only mask that's gonna savе us is duct tape on they mouths Big pharma doesn't cure you, dawg 'Cause every patient that gets cured is a customer lost Tom McDonald - Brainwashed

相关视频

Dr. Sabine Hazan, a leading expert in gastroenterology and microbiome research, sheds light on a critical issue in the pharmaceutical industry: the abandonment of off-patent drugs in favor of high-priced "orphan" treatments. "Hydroxychloroquine and ivermectin are off-patent. Once a drug loses exclusivity, profit margins shrink—sometimes to as little as $300 per treatment. Big Pharma isn’t interested in $300 drugs. They want blockbuster biologics and orphan drugs, where they can name their price. They’ll take a rare genetic condition, classify it as ‘orphan,’ and suddenly charge whatever they want. Look at the shift from Prilosec (a few hundred dollars) to biologics like Remicade—$10,000 a month. Once that door opened, every company followed. Now, they refuse to go back."* The problem? Research costs are high, but innovation is being stifled. There’s a deliberate movement suppressing off-patent drugs—like hydroxychloroquine and ivermectin—despite their potential. Why? Because the system is built to chase profit, not cures. The attacks on affordable, repurposed medicines aren’t about science—they’re about control. "The industry won’t reverse course. They’ll keep pushing expensive ‘innovations’ while ignoring proven, low-cost solutions. Patients lose. Medicine loses. When will it stop?" — Dr. Sabine Hazan The fight for unbiased research and accessible medicine continues. Share if you believe in putting patients over profits.

Camus

12,680 次观看 • 11 个月前

Dr. William Makis Exposes the Cancer Industry's Suppression of Generic, Life-Saving Drugs For over 15 years, preclinical research has consistently pointed to a shocking truth: cheap, widely available generic drugs like Ivermectin and Mebendazole show significant promise in fighting cancer. Yet, as Dr. William Makis reveals, this breakthrough science is being systematically ignored and suppressed. Why? The answer lies not in medical efficacy, but in profit. As Dr. Makis explains, both Ivermectin and Mebendazole have been off-patent since the mid-1990s. They are inexpensive to manufacture and cannot generate the massive, recurring revenue streams that the cancer industry is built upon. A cure that costs pennies is a threat to a multi-billion dollar business model. This is not a conspiracy theory; it is a documented strategy. Dr. Makis points to the shocking 2021 action by Johns Hopkins University, which secured a patent on Mebendazole despite it being an existing, FDA-approved generic drug. This move is a classic tactic of "evergreening" – not to promote research for the public good, but to control and potentially stifle it. By patenting a known compound for a new use (cancer), they create a legal monopoly. The goal isn't to inform the world of a potential cure; it's to own it, control its narrative, and prevent widespread, low-cost investigation and use by independent physicians. Doctors have the right to prescribe FDA-approved drugs "off-label." The existence of a promising, low-cost option should be revolutionary news. Instead, as Dr. Makis attests, those who dare to discuss it face coordinated attacks and a wall of silence from institutions that prioritize profit over patients. The case is open and shut. The drugs are real. The science is there. The motive for suppression is glaringly obvious. It’s time to demand answers and prioritize patient lives over pharmaceutical patents.

Camus

11,864 次观看 • 10 个月前